Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +17.14%. A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of $0.39 per share when it actually produced a loss of $0.32, delivering a surprise ...